Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Medications not intended for treatment of dyslipidemias and with a variable effect on lipids.

Whayne TF, Mukherjee D.

Curr Pharm Des. 2014;20(40):6325-38. Review.

PMID:
24953390
2.

Effect of antipsychotic medications on glucose and lipid levels.

Chaggar PS, Shaw SM, Williams SG.

J Clin Pharmacol. 2011 May;51(5):631-8. doi: 10.1177/0091270010368678. Epub 2010 Apr 21. Review.

PMID:
20410451
3.

Management of dyslipidemia in patients with human immunodeficiency virus.

Shalit P.

Rev Cardiovasc Med. 2014;15 Suppl 1:S38-46. Review.

PMID:
24987862
4.

Lipid metabolism in treated HIV Infection.

Dubé MP, Cadden JJ.

Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):429-42. doi: 10.1016/j.beem.2011.04.004. Review.

PMID:
21663837
5.

Lipid effects of antihypertensive medications.

Deano R, Sorrentino M.

Curr Atheroscler Rep. 2012 Feb;14(1):70-7. doi: 10.1007/s11883-011-0214-z. Review.

PMID:
22037772
6.

Mechanism of differential effects of antihypertensive agents on serum lipids.

Brook RD.

Curr Hypertens Rep. 2000 Aug;2(4):370-7. Review.

PMID:
10981172
7.

Dyslipidemia and lipid management in HIV-infected patients.

Lo J.

Curr Opin Endocrinol Diabetes Obes. 2011 Apr;18(2):144-7. doi: 10.1097/MED.0b013e328344556e. Review.

8.

Dyslipidemia related to antiretroviral therapy.

Estrada V, Portilla J.

AIDS Rev. 2011 Jan-Mar;13(1):49-56. Review.

PMID:
21412389
9.
10.

A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.

Bain AM, White EA, Rutherford WS, Rahman AP, Busti AJ.

Pharmacotherapy. 2008 Jul;28(7):932-8. doi: 10.1592/phco.28.7.932. Review.

PMID:
18576908
11.

Hyperglycemia and antipsychotic medications.

Haupt DW, Newcomer JW.

J Clin Psychiatry. 2001;62 Suppl 27:15-26; discussion 40-1. Review.

12.

Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics.

Tarr PE, Rotger M, Telenti A.

Pharmacogenomics. 2010 Apr;11(4):587-94. doi: 10.2217/pgs.10.35. Review.

PMID:
20350140
13.

Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999-2010.

Wong HK, Ong KL, Cheung CL, Cheung BM.

Ann Epidemiol. 2014 Jul;24(7):516-21.e1. doi: 10.1016/j.annepidem.2014.05.001. Epub 2014 May 10.

PMID:
24935464
14.

HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.

Kotler DP.

J Acquir Immune Defic Syndr. 2008 Sep 1;49 Suppl 2:S79-85. doi: 10.1097/QAI.0b013e318186519c. Review.

PMID:
18725816
15.

Addressing cardiometabolic risk during treatment with antipsychotic medications.

Amiel JM, Mangurian CV, Ganguli R, Newcomer JW.

Curr Opin Psychiatry. 2008 Nov;21(6):613-8. doi: 10.1097/YCO.0b013e328314b74b. Review.

16.

Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension.

Tse L, Procyshyn RM, Fredrikson DH, Boyda HN, Honer WG, Barr AM.

Int Clin Psychopharmacol. 2014 May;29(3):125-37. doi: 10.1097/YIC.0000000000000014. Review.

PMID:
24169026
17.

Lipid management in human immunodeficiency virus.

Myerson M.

Cardiol Clin. 2015 May;33(2):277-98. doi: 10.1016/j.ccl.2015.01.003. Review.

PMID:
25939300
18.

Evaluation and management of dyslipidemia in patients with HIV infection.

Green ML.

J Gen Intern Med. 2002 Oct;17(10):797-810. Review.

19.
20.

Supplemental Content

Support Center